Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cyberonics, Sorin Seek Critical Mass With Merger

This article was originally published in The Gray Sheet

Executive Summary

The yet-to-be-named combined company is predicting big opportunities, particularly, heart failure, sleep apnea and cardiac surgery.

You may also be interested in...



Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered

Boston Scientific and Cyberonics report disappointing data on vagus nerve stimulation to treat heart failure at the European Society of Cardiology conference in Barcelona. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.

Pipeline Watch: Japan Dominates This Week's 26 Approvals Plus 13 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Alter Pharma Group Rebrands As A.forall

Alter Pharma Group – including its US generics operation Milla Pharmacuticals, focused on niche injectables and solutions – has rebranded as A.forall.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel